Concepedia

Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study

Ting Deng, Le Zhang, Xiao-jian Liu, Jian-Ming Xu, Yu-Xian Bai, Yan Wang, Yu Han, Yuhong Li, Yi Ba

Medical Oncology · 2013 · 16 citations · 15 references

DOI

Concepts

References

15

FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study

Christophe Tournigand, Thierry André, Emmanuel Achille et al. · Journal of Clinical Oncology · 2003 · 2.9K citations · Full text

, , +13

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

Bruce J. Giantonio, Paul J. Catalano, Neal J. Meropol et al. · Journal of Clinical Oncology · 2007 · 2.3K citations

, , +15

EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

Alberto Sobrero, Joan Maurel, Louis Fehrenbacher et al. · Journal of Clinical Oncology · 2008 · 952 citations · Full text

, , +14

Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study

Charles S. Fuchs, John L. Marshall, Edith P. Mitchell et al. · Journal of Clinical Oncology · 2007 · 857 citations

, , +17

Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer

Herbert I. Hurwitz, Louis Fehrenbacher, John D. Hainsworth et al. · Journal of Clinical Oncology · 2005 · 685 citations

, , +13